Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Onco LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +2.20% 46.50p 45.00p 48.00p 46.50p 45.50p 45.50p 410,543 16:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Real Estate Investment & Services 0.0 -13.2 -17.0 - 37.63

Advanced Oncotherapy PLC Technological update

04/09/2017 7:00am

UK Regulatory (RNS & others)

Advanced Onco (LSE:AVO)
Historical Stock Chart

6 Months : From Jun 2017 to Dec 2017

Click Here for more Advanced Onco Charts.


RNS Number : 6608P

Advanced Oncotherapy PLC

04 September 2017


("Advanced Oncotherapy" or the "Company")

Technological update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, with successful integration of three key elements of the device. The first Side Coupled Drift Tube Linac ("SCDTL") accelerating module has been integrated with the Radiofrequency Quadrupole ("RFQ") and proton source, with functionality of the combination and further proton acceleration confirmed through the measurement of the proton beam through all integrated units.

On 6 March 2017, the Company announced the acceleration of a proton beam through the integrated proton source and RFQ, at the maximum design-anticipated energy of 5 MeV.

The addition of the first SCDTL is significant as:

1. It is the first module in the next group of accelerating structures i.e. the SCDTLs. This successful integration confirms the SCDTL design concept and will facilitate the addition of subsequent SCDTL modules.

2. The proton beam was recorded at 7.5MeV, as expected. This achievement further validates the design, manufacturing and integration of the LIGHT system.

3. As with the RFQ, acceleration of the proton beam at relatively low energies is more challenging than at higher ones; this result is, therefore, an important milestone in LIGHT's development.

When fully integrated with the proton source and RFQ, it is anticipated that four SCDTLs will be capable of producing a proton beam of 37.5MeV.

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "All of our tests to generate and accelerate a proton beam have been successful and this represents significant progress in validating the capabilities of the first in the next group of accelerating components. This is another notable achievement for the team in Geneva and paves the way for the integration and validation of subsequent SCDTL modules.

"We can confirm that, following these successful trials, the Company remains on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018."

For further information, please contact:

    Advanced Oncotherapy Plc 
  Dr. Michael Sinclair,            Tel: +44 20 3617 8728 
   Executive Chairman 
  Nicolas Serandour, CEO 
  Stockdale Securities (Nomad 
   & Joint Broker) 
  Antonio Bossi / David            Tel: +44 20 7601 6100 
  Stifel Nicolaus Europe 
   (Joint Broker) 
  Jonathan Senior / Ben            Tel: +44 20 7710 7600 
  Walbrook PR (Financial        Tel: +44 20 7933 8780 or 
   PR & IR)                  
  Paul McManus / Anna Dunphy     Mob: +44 7980 541 893 / 
                                   Mob: +44 7876 741 001 

About Advanced Oncotherapy Plc

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange



(END) Dow Jones Newswires

September 04, 2017 02:00 ET (06:00 GMT)

1 Year Advanced Onco Chart

1 Year Advanced Onco Chart

1 Month Advanced Onco Chart

1 Month Advanced Onco Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:gb D:20171214 22:29:29